Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

NCT04967196 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Unresectable Melanoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
PROCEDURE: Lymph Node Assessment
PROCEDURE: Biospecimen Collection

Sponsor

Mayo Clinic